Rigosertib Sodium

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C71355

A substance being studied in the treatment of cancer. It blocks certain proteins that are needed for cell growth and may kill cancer cells. ON 01910.Na is a type of protein kinase inhibitor and a type of benzyl styryl sulfone analog.

592542-60-4

C21H24NO8S.Na

C71355

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

GDC

FDA

The sodium salt form of rigosertib, a synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.

Rigosertib Sodium

406FL5G00V

ON 01910.Na

RIGOSERTIB SODIUM

Rigosertib Sodium

Polo-like kinase 1 Inhibitor ON 01910.Na

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C30006

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

Rigosertib Sodium

Polo-like_kinase_1_Inhibitor_ON_01910_Na

Rigosertib Sodium

573371

573371

573371

Rigosertib Sodium

Thesaurus:C71355

Rigosertib Sodium

Pharmacologic Substance

C3467794

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1404

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129825